CDK
Os inibidores das quinases dependentes de ciclinas (CDK) são compostos que bloqueiam a atividade das CDKs, um grupo de quinases de proteínas que regulam o ciclo celular, a transcrição e outros processos celulares. As CDKs são ativadas pela ligação às ciclinas, e sua atividade é crucial para a progressão das células através das diferentes fases do ciclo celular. Inibir as CDKs pode interromper a divisão celular, levando à parada do ciclo celular e à apoptose, especialmente em células cancerígenas onde as CDKs frequentemente estão desreguladas. Os inibidores de CDK são amplamente utilizados na pesquisa do câncer e têm potencial terapêutico no tratamento de vários tipos de câncer. Na CymitQuimica, oferecemos uma seleção abrangente de inibidores de CDK de alta qualidade para apoiar sua pesquisa em controle do ciclo celular, câncer e desenvolvimento terapêutico.
Foram encontrados 541 produtos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CDK8-IN-12
CAS:CDK8-IN-12: selective CDK8 inhibitor (Ki 14 nM), oral anticancer, blocks GSK-3α/β, PCK-θ, halts MV4-11 cell growth.Fórmula:C21H20ClN3O2Pureza:98.55% - 99.22%Cor e Forma:SoildPeso molecular:381.86Ref: TM-T72048
1mg52,00€5mg101,00€10mg150,00€25mg250,00€50mg363,00€100mg509,00€200mg695,00€1mL*10mM (DMSO)116,00€TMX-2138
CAS:TMX-2138 is a CDKs PROTAC degrader, with IC50 values of 8.7 nM for CDK1/cyclinB, 10.9 nM for CDK2/cyclinA, 7.0 nM for CDK5/p25, and 25.7 nM for CDK9/cyclinT1. It enhances the ubiquitination and degradation of CDKs and is utilized for ovarian cancer research.Fórmula:C40H43BrFN9O11SCor e Forma:SolidPeso molecular:956.791LL-K8-22
LL-K8-22: potent CDK8/cyclin C degrader; DC50 ~2.5μM; hinders STAT1 phosphorylation; curbs E2F/MYC cancer pathways; for TNBC study.Fórmula:C37H43N5OCor e Forma:SolidPeso molecular:573.77FDA-Approved Kinase Inhibitor Library
A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.
Cor e Forma:LiquidYKL-5-124 TFA
CAS:YKL-5-124 TFA is a potent CDK7 inhibitor (IC50: 53.5 nM), more than 100x selective over CDK9/2, not active on CDK12/13, and disrupts the cell cycle.Fórmula:C30H34F3N7O5Cor e Forma:SolidPeso molecular:629.63XY028-133
CAS:XY028-133 is a PROTAC-based CDK4/6 degrader for the study of tumors.
Fórmula:C53H67N11O7SPureza:97.11%Cor e Forma:SolidPeso molecular:1002.23CDK4/6-IN-11
CAS:CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader.Fórmula:C43H49N11O7Cor e Forma:SolidPeso molecular:831.92PROTAC CDK9 degrader 4
CAS:PROTAC CDK9 degrader 4 is a CDK9 degrader that targets transcriptional regulation and has potential anticancer activity.Fórmula:C43H56N10O5Cor e Forma:SolidPeso molecular:792.97CDK4/6-IN-23
CDK4/6-IN-23 (Compound 42) is a potent and selective inhibitor of CDK4/6, displaying an IC50 of 11 nM for CDK6. This compound significantly activates immune cells and enhances IL-3 production. In mice undergoing 5-FU chemotherapy, CDK4/6-IN-23 demonstrates dual bone marrow protection and immunomodulatory effects.Fórmula:C32H34FN7O4Cor e Forma:SolidPeso molecular:599.655WAY-322243
CAS:WAY-322243 has antibacterial and anti-inflammatory activity and has an inhibitory effect on CLK-1, which can be used to study Alzheimer's disease.Fórmula:C18H18N2O2SPureza:99.88%Cor e Forma:SoildPeso molecular:326.41MeBIO
CAS:MeBIO is an agonist of aryl hydrocarbon receptor, with IC50 of 44 and 55 μM for GSK-3 and CDK1/CyclinB, respectively. MeBIO does not affect GSK-3β.Fórmula:C17H12BrN3O2Pureza:99.64%Cor e Forma:SolidPeso molecular:370.2Ref: TM-T21966
1mg39,00€5mg74,00€10mg117,00€25mg220,00€50mg354,00€100mg520,00€500mg1.130,00€1mL*10mM (DMSO)86,00€CDK1-IN-2
CAS:CDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM.Fórmula:C17H11ClN2OPureza:98.53%Cor e Forma:SoildPeso molecular:294.73Ref: TM-T64373
1mg50,00€5mg107,00€10mg170,00€25mg354,00€50mg567,00€100mg810,00€500mg1.644,00€1mL*10mM (DMSO)103,00€Cell Cycle Compound Library
A unique collection of xnum cell cycle related compounds for high throughput screening (HTS) and high content screening (HCS);
Cor e Forma:Odour SolidCDK4/6-IN-5
CAS:CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)Fórmula:C22H28ClFN6O4SCor e Forma:SolidPeso molecular:527.01HS-243
CAS:HS-243 is an inhibitor of IRAK-4 and IRAK-1 with IC50s of 20 and 24 nM. HS-243 shows anti-inflammatory and anticancer activity.
Fórmula:C17H16N4O3Pureza:98.62%Cor e Forma:SolidPeso molecular:324.33CDK-IN-12
CAS:CDK-IN-12 (Example 20), a CDK inhibitor, effectively inhibits CDK4/6, demonstrating IC50 values below 20 nM [1].Fórmula:C26H29FN6OSCor e Forma:SolidPeso molecular:492.61JH-XVI-178
CAS:JH-XVI-178: potent CDK8/19 inhibitor with good pharmacokinetics, low clearance, moderate oral bioavailability.Fórmula:C22H22ClN7OCor e Forma:SolidPeso molecular:435.92HTH-01-091 TFA
HTH-01-091 TFA: Potent, selective MELK inhibitor (IC50=10.5 nM); also targets PIM1/2/3, RIPK2, DYRK3, smMLCK, CLK2; used in breast cancer research.Fórmula:C28H29Cl2F3N4O4Cor e Forma:SolidPeso molecular:613.46CDK2 degrader 3
CAS:CDK2 degrader3 selectively degrades CDK2 and exhibits antitumor activity.Fórmula:C44H53ClN10O6SCor e Forma:SolidPeso molecular:885.47CDK2/Bcl2-IN-1
CDK2/Bcl2-IN-1 (compound 1) is a saponin-based inhibitor of CDK-2 (IC50=117.6 nM) that exhibits potent cytotoxic effects on cancer cells.Fórmula:C35H56O10SPureza:98%Cor e Forma:SolidPeso molecular:668.88
